Quick Take Selpercatinib in RET -Mutant Medullary Thyroid Cancer November 15, 2023 DOI: 10.1056/NEJMdo007277 Save ...

Researchers conducted a population-based cohort study to estimate the prevalence of major thyroid cancer-associated syndromes.

Your thyroid gland may be small, but it plays a big role in keeping your body running. Located at the base of your neck where ...

The Food and Drug Administration (FDA) has granted traditional approval to Retevmo ® (selpercatinib) for adult and pediatric patients 2 years and older with advanced or metastatic medullary ...

An expert discusses the recent approval for Retevmo for RET-positive pediatric thyroid cancer and ongoing research for this patient population. The recent Food and Drug Administration (FDA) approval ...

Selpercatinib, an oral, selective, brain-penetrant RET kinase inhibitor, was compared with multikinase inhibitors in advanced medullary thyroid cancer. At 12 months, progression-free survival was ...

The review discusses the early trials of multikinase tyrosine kinase inhibitors (TKIs) that were initially used to treat RET-altered thyroid cancer and NSCLC, with limited success. The development ...

The data showed the annual incidence of thyroid cancer in the United States increased from 5.0 cases per 100,000 people in 1975 to 14.6 cases per 100,000 people in 2009.